ERA-NET to support the Joint Programming Initiative on Antimicrobial resistance (JPIAMR)

Topic description

Specific Challenge:

Antimicrobial resistance (AMR) is a serious challenge that has reached alarming levels in the EU and globally. There is an urgent need to address this major health threat by actions that should include boosting research and innovation as well as strengthening coordination and cooperation in this area

The Joint Programming Initiative on Antimicrobial resistance (JPIAMR) enables the participating countries that include EU Member States and other countries on five different continents, to address the global threat of AMR. It allows the establishment, alignment and building of national research programmes to increase their effectiveness and the impact of research efforts.

Building on earlier successes in implementing the JPIAMR Strategic Research Agenda, in scaling up research efforts and establishing synergies with Horizon 2020, there is a need to continue and consolidate the successes in defragmentation, better coordination and alignment amongst the countries participating in JPIAMR. In addition to this, there is a need to boost research, development and innovation on AMR and improve global coordination in this area as stated in the European One Health Action Plan against AMR^[1].

Proposals should pool the necessary financial resources from participating national or regional research programmes in the area of AMR by implementing a transnational joint call for proposals resulting in grants to third parties with EU co-funding. This should scale up the implementation of the JPIAMR Strategic Research Agenda and the European One Health Action Plan against AMR. Proposals must also implement other joint activities, including additional calls without EU co-funding.

Proposals should take the full One Health approach into account. They should aim at supporting research and innovation for the development and testing of strategies and methodologies to reduce the transmission and spread of AMR. They should also further align national research plans and strategies in Europe and beyond. Proposals should demonstrate the expected impact on national and transnational programmes as well as the leverage effect on European research and competitiveness.

Participation of legal entities from third countries, and/or regions including those not automatically eligible for funding in accordance with General Annex A, is encouraged in the joint call as well as in other joint activities including additional joint calls without EU co-funding. Participants from countries not listed in General Annex A are eligible for EU funding under this topic and may request a Union contribution (on the basis of the ERA-NET unit cost) only for the coordination costs of additional activities. The proposal should demonstrate that these co-funded other activities exclude any overlaps with related on-going actions co-funded by the EU under Horizon 2020.The Commission considers that proposals requesting a contribution from the EU of minimum EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

• Funding of research proposals on a topic identified in the JPIAMR Strategic research agenda, which needs to be addressed at European level or wider, and which is complementary to topics of the EC work programmes.
• Leverage transnational excellent research with EU-added value in the area of AMR.
• Increased commitment of participating countries to the implementation of the JPIAMR Strategic research agenda
• Strengthening and supporting the implementation of the European One Health Action Plan against AMR.
• Strengthening alignment of national and regional plans and activities in the area of AMR research.
• Enhancement and/or better exploitation of national or EC-supported activities.

ERA-NET
International cooperation

[1]https://ec.europa.eu/health/amr/sites/amr/files/amr_action_plan_2017_en.pdf